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sure by demanding early decisions and rapid access. Decision makers may unduly 
delay potential benefits to patients by waiting for stronger evidence, or may endorse 
medicines that later turn out to have a less robust benefit-risk ratio, to be ineffective, 
cost-ineffective, or even harmful. Hence, many countries have developed mechanisms 
that allow temporary access to promising medicines while concurrently requesting the 
generation of additional evidence to reduce uncertainty. Their objective is an optimal 
trade-off between different stakeholder needs, flexibility, responsiveness, and rigor as 
well as the flexibility to revise decisions on access when new evidence becomes avail-
able. The ENCePP WG on HTA has the potential to become a capacity building tool for 
regulatory and HTA agencies to develop research structures aimed at complementing 
the evidence generation for MA and market access. Post-authorisation studies devel-
oped under the auspices of ENCePP could provide new safety and clinical effectiveness 
information of marketed medicines. ENCePP expertise, research experience and health 
care databases may also contribute to the coordination, methodological guidance and 
data sourcing for the enhancement of HTA processes.
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Objectives: Main function of a health system is to prevent diseases, restore health 
status and reduce health impairment. Health systems are mainly organized on effi-
cacy based decisions, but sometimes their social functions modulate this principle. 
In case of small patient groups, end-stage status and unmet health needs, usually 
decision are made on the basis of equity, instead of efficacy. These demands create 
special development conditions; eventuate in high prices on the supply side, therefore 
cost-effectiveness cannot be guaranteed, not even with substantial health benefits. 
Numerous expensive drug therapies are available in Hungary with reimbursement, 
but due to fiscal restrictions, new therapies are not able to access reimbursement. 
These tendencies create a paradox situation, since equity is implemented occasionally 
in absence of objective criteria. Due to the huge differences among these therapies, a 
standardized decision-making principle does not exist, but a general framework can 
be developed. In our study, methods and techniques are introduced, which can help to 
assess these therapies and organize a transparent system. MethOds: For the general 
assessment of therapies, many methods are available. In our research, we reviewed 
these tools and investigated their combinability in the special situation of “high-
value” therapies. Results: A wide range of evidences (clinical trials, meta-analysis, 
health-economy analysis, HTAs) provide a robust background to compare high-value 
therapies between different therapeutic areas. Outputs (LYG, OS, QALY, costs etc.) 
show a significant variation following different clarification process. A standard-
ized process needed to earn comparable outputs from evidences. cOnclusiOns: As 
we found, these tools could help decision making on prioritizing therapies, allocate 
resources with a higher control and reduce the risk of reimbursement.
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Orphan Drug Legislation incentivises the development of treatments for rare dis-
eases that would otherwise not be profitable investment opportunities. However, 
with budgets squeezed and diseases increasingly stratified, we question whether 
this legislation is fit for purpose. Segmenting diseases into genetically-defined sub-
groups, most notably among some cancers, has enabled increased pharmacological 
targeting. Common diseases are thus being reconsidered as multiple rare conditions, 
each eligible for orphan designation, entitling the treatments to the economic ben-
efits afforded by legislation. Stratification also occurs in diseases which are already 
rare (e.g. cystic fibrosis), and new treatments, such as ivacaftor, are being developed 
to target specific mutations. Orphan status for a drug is maintained regardless of 
whether the overall population size, for which the drug is licensed, exceeds prevalence 
thresholds enabling companies to take a strategic approach to development. The high 
prices of orphan drugs impact on access. However, typical cost-effectiveness thresh-
olds are often waived suggesting that greater value is placed on treatments for rare 
conditions, compared with prevalent diseases that are equally severe and debilitating. 
Population surveys indicate that funding policies that take resources from elsewhere 
in health economy budgets to fund these treatments are not in the public interest. 
At the same time, research and development into certain common diseases such as 
stroke, where the burden is much higher, has been somewhat neglected. We believe 
it is time to revisit orphan drug legislation. Regulators should be able to limit the 
benefits of orphan designation should the cumulative eligible population exceed a 
certain threshold. More robust criteria need to be applied for defining a “medically 
plausible subset” and pricing should to be brought closer in line with drugs for non-
rare diseases. Furthermore, the focus of incentives should move more towards areas 
of unmet need where disease burden is greatest.
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In this paper, we review a well-known phenomenon of »me-too« drugs in the pharma-
ceutical branded markets, which has gained wide attention during the recent years. 
A branded “me-too” drug is deemed having somewhat similar therapeutic effect as 
the “breakthrough” drug, although from an intellectual property right perspective, 
there is no difference between the two. Definition of “me-too” drugs has yet to reach 
consensus and it would likely be ferociously disputed by the branded firms. When the 
first branded »me-too« drug enters the market, we are dealing with oligopoly, or more 
precisely, duopoly, described by Cournot model. From an oligopoly model, we would 
expect at Nash equilibrium both price to decrease and total volume to increase com-
pared to shared monopoly conditions. An oligopolistic structure of a »me-too« phar-
maceutical market puts substantial emphasis on branding and promotion (to achieve 
Objective: Pharmaceutical pricing is characterized by a consistent variability across 
markets. Social and economic differences represent only the easiest-to-predict reason 
for such variability. Stricter regulatory hurdles, market landscape, challenging nego-
tiation processes, varying business strategies, and sometimes unplanned outcomes 
of pharma launch decisions concur in the final price for a specific drug. A better 
understanding of price trends and out-patterns is a useful insight to help improving 
pricing strategies by targeting realistic pricing expectations, and studying competi-
tors’ pricing mistakes and successes. This paper shows the price variability of ten 
different pharmaceuticals in ten key markets (France, Germany, UK, Italy, Spain, US, 
Brazil, Russia, India, and China). Common trends, similarities and particularities are 
discussed. MethOds: Using PRICENTRICTM data, we collected ex-factory prices for 
various oncology products, and we defined whether a country fell into a HTA sys-
tem or free pricing group. We also compared the product prices to GDP per capita 
(International Monetary Fund 2012) to investigate trends between the two parameters. 
The analysis investigates two key areas: 1. Difference in price depends on social, eco-
nomic considerations but also by the nature and complexity of market access process 
2. The relationship between prices and GDP per capita across countries. Results: The 
US and Germany have the highest prices of all studied countries. They are also the 
only two countries where prices are freely set by manufacturers. Prices are slightly 
higher in countries having a high GDP per capita. However, countries like France and 
UK having strong HTA authorities and pricing regulations do have a small correlation 
to this trend line. cOnclusiOn: Our analysis shows that pricing and pharma strate-
gies can be based on countries’ economic situation. Nevertheless, formal established 
HTA bodies with clear pricing rules help controlling pricing.
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Collaboration with health care stakeholders is a fundamental component of a sys-
tems-based health care economy, and it will become the dominate business model 
going forward. Yet most health care industry stakeholders are failing to accept this 
inevitable transition. While many acknowledge the need to move toward a more 
integrated “systems thinking” approach – one that maps influence patterns, ampli-
fies interdependencies, and drives collective outcomes, they struggle with actual 
implementation. A viable and sustainable information network provides the struc-
ture, aligned incentives and competitive collaboration the bricks and mortar, and 
trust the cornerstone. Until they can build that and foster a culture of transparency, 
they won’t achieve the cost and innovation benefits inherent in these cross-industry 
partnerships. Although health care stakeholders know they need to partner with 
others to be successful in this new systems-thinking economy, they need actionable 
strategies to demonstrate how the benefits of ongoing collaborations far outweigh 
the risks. This podium presentation will present original research aimed to qualify 
stakeholder perceptions on alignment and collaboration around the delivery of health 
care, in addition to critical hurdles they must overcome. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers provides insight into 
their needs, their disparate perceptions, and their levels of confidence in the ability to 
shift to a systems-thinking collaborative culture. Approximately 25% of respondents 
stated they were not aligned with other stakeholders, though agree they need better 
alignment and foresee closer collaboration in the future. Over 70% of stakeholders 
believe data transparency and information-sharing is critically important to a suc-
cessful and interoperable health care system, yet very few from each group were 
willing to demonstrate such transparency. Further detail will be given on insights and 
challenges gleaned from interviewing large and small stakeholders as well as practical 
strategies to guide the transformation to a systems-thinking industry.
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The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) is a project led by the European Medicines Agency aimed at further strength-
ening the post-authorisation monitoring of medicinal products in Europe by facilitat-
ing the conduct of multi-centre, independent post-authorisation studies focusing on 
safety and benefit/risk assessment. ENCePP has recently established a WG on HTA 
to develop methodological guidance to supplement the efficacy and safety aspects 
of medicines known at the time of marketing authorisation (MA) and to bridge the 
needs of HTA and post-marketing benefit-risk assessments. Decision makers are often 
faced with the challenge that long-term, real-world data on safety and effectiveness is 
lacking at the time of MA. This creates uncertainty around the medicines’ risk-benefit 
profile while manufacturers, health care providers, and patient groups exert pres-
A492  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
essary duplication of effort must be eliminated. However, doing so is difficult due to 
the current culture of data protectionism and a lack of suitable software that enables 
convenient and useful sharing of the intermediate results. AppROAch: Building on 
our previously published reviews of software for systematic review and trial analyt-
ics, the talk identifies the technical and cultural challenges to be met. We propose 
that a web-based solution enabling the global research community to contribute 
their intermediate results in exchange for access to the data contributed by others 
could rapidly gain momentum. Such a system would challenge data protectionism by 
greatly reducing the level of investment required for data acquisition. cOnclusiOn: 
A disruptive web-based system enabling a massively collaborative approach to sys-
tematic reviewing can make data protectionism obsolete and eliminate much of the 
effort required for future systematic reviews.
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Value-BaseD Pricing in tHe uk anD Potential Patient access HurDles 
to innoVatiVe Drugs
Papadopoulou K., Grosvenor A.
PriceSpective, London, UK
The UK government plans to introduce value-based pricing (VBP) for medicines in 
England and Wales from January 2014, and one of the key tenets of the scheme is 
to improve patient access to new innovative drugs. This poster aims to explore the 
extent to which VBP is likely to achieve this goal. To meet this objective, an in-depth 
review of available literature (including white papers from key stakeholders and sci-
entific publications) was conducted. Targeted interviews with five leading thought-
leaders in the implementation of VBP were also conducted to support analysis. 
Research identified a number of areas of uncertainty in VBP implementation that 
could detrimentally impact patient access to new drugs. First, the timeline for the 
VBP negotiation process remains unclear. Currently, it takes NICE on average 48 
weeks to issue guidance on a single technology appraisal, which could be extended 
if a technology is not considered cost-effective. Under VBP, manufacturers will still 
be required to negotiate their price with the Department of Health if the calculated 
VBP price by NICE is unfavorable, and the VBP HTA methodology itself could be more 
complex than the current cost-per-QALY approach. Protracted negotiations could 
also delay access in Scotland and Northern Ireland. Equally, manufacturers may 
postpone launch in the UK if they consider VBP a threat in their price corridor in 
other markets. Finally, it is not clear if additional regional or local level negotiations 
will take place, which could further delay access. In conclusion, although there is 
potential for the new adjustable QALY threshold (which remains to be confirmed) 
to foster innovation, the ability of the new VBP process to expedite patient access 
remains uncertain.
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A choice of business for the pharmaceutical industry “Seguro Popular” in Mexico. 
Abstract Mexico has various providers of health services each one determined to 
a sector of the population where we can find the Mexican Social Security Institute 
(IMSS) that is specifically for workers in the private sector employees and their 
families, the Institute for security and services social of the State workers (ISSSTE) 
for workers in the service of the State or public sector and their families starting 
2003 ushered to the Seguro Popular that extends to the population without social 
security or in State of helplessness in these three mentioned health are emerg-
ing as institutions providing health services larger Mexico insomuch that by 2013 
the Seguro Popular has approximately 54 million affiliates number of successful 
membership in less than 10 years in a country where there is little more than 110 
million of people Seguro Popular is placed, on par with the historic and hegemonic 
IMSS, as the largest buyer of drugs, aware of this are his consumption figures that 
since 2008 has been made public, in such data can find that from 2008 to 2012 they 
have bought 1,241,637,748.68 US Dlls only in drugs consumption regularly since the 
Seguro Popular has several portfolios of services where separate regular conditions 
of sufferings of low frequency and high cost and conditions of very low frequency 
and high cost for children under 5 years who in turn have specific budgets.
Disease-sPecific stuDies 
gastrointestinal DisorDers – clinical outcomes studies
Pgi1
unDerstanDing tHe effect of clostriDium Difficile infection on 
HosPital mortality in englanD, tHe netHerlanDs, anD sPain
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Objectives: Increasing rates of Clostridium Difficile Infection (CDI), a hospital-acquired 
infection, has stimulated a number of financial incentives and government spon-
sored initiatives to quell the spread of the disease. Previous research has shown the 
impact of CDI on hospital length of stay to attempt to quantify the resource impli-
cations. The purpose of this study is to evaluate the impact of CDI on in-hospital 
mortality. MethOds: Data were obtained from national hospital episode databases 
in England, The Netherlands, and Spain. Only patients over the age of 50 and those 
diagnosed with diabetes, chronic kidney disease, heart failure, and chronic obstructive 
pulmonary disease (COPD) were included in the analysis. Cases of CDI were stratified 
between hospital-onset and community-onset cases. Only those that were assumed 
to be hospital-onset were included in the analysis. A logistical regression was used to 
predict the relative effect hospital-onset CDI had on in-hospital mortality. A number 
of covariates were controlled for including: age, sex, comorbidities, and length of stay 
but varied between countries depending on the availability of data. Results: Patients 
with hospital-onset CDI had an overall higher mortality rate compared to those who 
horizontal differentiation), which is often cited (beside R&D costs) as the second barrier 
to entry to the branded market. Here, we have discussed several examples of Cournot 
model within various ATC4 groups and jurisdictions. We have also critically examined 
preponderance of »me-too« entries, particularly in the light of an R&D investment of 
the branded firms. Historically, »me-too« drugs are more ubiquitous than often real-
ized by regulatory agencies, payers, and also the pharmaceutical industry itself. This 
unfortunately presents an inefficient use of resources as the breakthough innovation 
is nowadays, in the time of austerity measures, a real necessity. The models that would 
give incentives to the industry to invest in R&D for breaktrough therapies are possible 
and would not only contribute to optimization of societal welfare but would also in 
the long run increase an R&D productivity of branded firms.
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This poster seeks to highlight the key challenges and opportunities surrounding patient 
access to innovative cell therapies in the EU5 and US. The findings are based on second-
ary research of commercialised cell therapies as well as primary research with payers 
in EU5 and US. Cell therapies have a unique opportunity to improve patient outcomes 
but face their own set of challenges due to being cell based. As many of these thera-
pies involve manipulation of the patients’ own cells before being reintroduced (e.g., 
ChondroCelect), the associated side effects are likely to be minimal. Other therapies 
(e.g., gene therapy, Glybera) involve the introduction of foreign genetic material but 
provide a potential long-term cure. However, there are some important challenges that 
must be assessed when considering how to commercialise such therapies. In the case of 
therapies where a patient’s cells are manipulated ex vivo, who bears the risk if the patient 
does not receive their individualised treatment? For those therapies that purport to cure 
disease, how much are health care systems willing to pay for them and what evidence 
would be required in order to justify a high price? Moreover, for all therapies, there is the 
uncertainty regarding access pathways: will cell therapies necessarily undergo an HTA 
evaluation to gain access in the EU? What are the criteria that will be used to determine 
whether such a therapy is deemed a product (and, hence, undergo an assessment like 
a regular biopharmaceutical) or a procedure (and likely bypass a national evaluation)? 
In conclusion, cell therapies face uncertainties in market access and funding due to 
unestablished pathways for the spectrum of interventions that fit under the cell therapy 
umbrella. Until frameworks have been put in place, each cell therapy should be assessed 
individually in order to determine likely pathway to patient access.
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New discoveries are a critical priority for the pharmaceutical industry, for which 
the primary aim should be to address unmet medical needs. However, the use of 
fixed cost-effectiveness (ICER) thresholds for health technology assessment (HTA) 
may tend to decrease incentives to innovate and affect future treatment options. 
This presentation highlights, using a case study, the impact of recent generic drug 
price policies on pharmaceutical innovation in the context of fixed ICER thresh-
olds and proposes a new consideration for the cost-effectiveness analysis (CEA). 
There is a direct causal relationship between HTA and the market price of a drug; 
in jurisdictions where HTA agencies apply fixed ICER thresholds as an important 
reimbursement listing criterion, the incremental cost of a new drug is expected to be 
proportional to its incremental benefit over the comparator. However, the compara-
tor price is subject to market forces or sudden policies and may change markedly 
affecting the cost-effectiveness assessment (e.g. where the comparator patent has 
expired). Since recent generic price regulations (e.g. 18% or 25% of the innovative 
price in Canada) increased the price gap between drugs’ generic and patented ver-
sions, it is harder to achieve a sufficient level of incremental benefits in order to 
offset incremental prices of new treatments. This analysis thus demonstrates that 
with recent changes in generic drug prices in Canada and other jurisdictions, even 
promising drugs will have challenges to show attractive ICERs. Traditional decision-
making process should be adapted to reflect these changes and to promote innova-
tion in therapeutic fields with unmet medical needs. A compromise would be to 
include the comparator’s patented price in the CEA instead of the generic drug in 
certain areas of unmet needs. By identifying the relevant disease areas, decison 
makers and HTA authorities could convey the importance of investing in these 
therapeutic areas to manufacturers.
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bAckgROund: The scope of systematic reviews and health technology assessments 
is rapidly expanding due to increasing demand for more complex models that account 
for patient, treatment, and trial characteristics, network meta-analyses that include 
more interventions, and the growing number of clinical trials. By the year 2000, the 
effort required to publish a typical systematic review had already reached the thou-
sands of person-hours, which were predominantly spent on data acquisition tasks. 
Innovative solutions are required to prevent the costs of comparative effectiveness 
research from ballooning out of proportion. pRObleM: Typically only the end product 
of systematic reviewing, a report summarizing the evidence, is made widely avail-
able. However, capturing the intermediate results of literature searching, publication 
screening, and data extraction has the potential to greatly enhance the efficiency of 
future reviews. In the face of the increasing scope of systematic reviews, this unnec-
